Yttrium-90-labelled somatostatin-analogue for cancer treatment

Lancet

Volumn 351, Issue 9100, 1998, Pages 417-418

  Otte, A ^a   Mueller Brand, J ^b   Dellas, S ^b   Nitzsche, E U ^b   Herrmann, R ^b   Maecke, H R ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN B; FLUORODEOXYGLUCOSE F 18; MORPHINE; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; YTTRIUM 90;

ADULT; ARTICLE; BONE MARROW TOXICITY; CANCER PAIN; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; METASTASIS; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032492168     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)78355-0     Document Type: Article

References (4)

1. Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334: 246-54.
2. Krenning EP, Kooij PP, Pauwels S, et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 1996; 57 (suppl 1): 57-61.
3. 3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24: 368-71.
4. Otte A, Jermann E, Behe M, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24: 792-95.